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A B S T R A C T   
Four peptides with cytotoxic activity against BRIN-BD11 rat clonal β-cells were purified from the venom of the 
black-necked spitting cobra Naja nigricollis using reversed-phase HPLC. The peptides were identified as members 
of the three-finger superfamily of snake toxins by ESI-MS/MS sequencing of tryptic peptides. The most potent 
peptide (cytotoxin-1N) showed strong cytotoxic activity against three human tumor-derived cell lines (LC50 ¼
0.8 � 0.2 μM for A549 non-small cell lung adenocarcinoma cells; LC50 ¼ 7 � 1 μM for MDA-MB-231 breast 
adenocarcinoma cells; and LC50 ¼ 9 � 1 μM for HT-29 colorectal adenocarcinoma cells). However, all the 
peptides were to varying degrees cytotoxic against HUVEC human umbilical vein endothelial cells (LC50 in the 
range 2–22 μM) and cytotoxin-2N was moderately hemolytic (LC50 ¼ 45 � 3 μM against mouse erythrocytes). 
The lack of differential activity against cells derived from non-neoplastic tissue limits their potential for devel-
opment into anti-cancer agents. In addition, two proteins in the venom, identified as isoforms of phospholipase 
A2, effectively stimulated insulin release from BRIN-BD11 cells (an approximately 6-fold increase in rate 
compared with 5.6 mM glucose alone) at a concentration (1 μM) that was not cytotoxic to the cells suggesting 
possible application in therapy for Type 2 diabetes.   
1. Introduction 
The toxic peptides and proteins present in snake venoms undoubt-
edly arose by natural selection in order that the organism could subju-
gate prey and as a component of its defence strategy against predators. 
At first sight, it appears paradoxical that snake venoms, estimated to be 
responsible for between 81,000 and 138,000 fatalities and around three 
times as many amputations and other permanent disabilities each year 
(W.H.O. Fact Sheet, 2019), should represent an important source of 
compounds with therapeutic potential. These include peptides and 
proteins with broad-spectrum antibacterial (Charvat et al., 2018), 
antifungal (Cavalcante et al., 2017), antiparasitic (Allane et al., 2018) 
and antiviral (Chen et al., 2017) activities, as well as components whose 
anti-inflammatory (Sartim et al., 2018), anticoagulant (Khan et al., 
2018), wound healing (Thakur et al., 2019), anti-hypertensive (Almeida 
et al., 2017) and analgesic (Brzezicki and Zakowicz, 2018) properties 
have potential clinical relevance. Such compounds may show greater 
potency and increased stability compared with peptides derived from 
mammals. Recent advances in methodology, permitting purification and 
structural characterization of these components from small quantities of 
material (Calvete, 2018) has meant that snake venoms are becoming 
increasingly important as a source of natural products with the potential 
for development into therapeutically valuable drugs (Estev~ao-Costa 
et al., 2018; Lazarovici, 2020). 
There is a constant need for new types of anti-cancer agents partic-
ularly in cases where the tumor is not responsive to conventional 
pharmaceutical intervention due to the development of drug resistance 
(Lord and Ashworth, 2013). The presence in venoms of peptides and 
proteins with potent in vitro cytotoxic activity against tumor cells has 
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been described for a wide range of snake species, particularly those 
belonging to the Viperidae and Elapidae families [reviewed in (Vyas 
et al., 2013; Uzair et al., 2018; Zainal Abidin et al., 2019)]. However, to 
describe such peptides as “anti-cancer” or even “anti-tumor” is prema-
ture as no snake venom peptide has been shown to produce reduced 
tumor mass in clinical trials involving human subjects and there have 
been relatively few in vivo studies in animal models of cancer. In addi-
tion, although a particular peptide may show some selectivity for 
tumor-derived cells compared with non-neoplastic cells, the difference 
in cytotoxic potency is often insufficient to suggest the possibility of 
therapeutic application. 
The prevalence of type 2 diabetes mellitus (T2DM) is increasing 
worldwide and there is clearly a need for new effective agents that 
improve glucose tolerance and address the associated complications of 
the disease (Bailey, 2018). Long-standing T2DM is associated with a 
combination of insulin resistance and defective β-cell function and 
several snake venom-derived components have demonstrated in vitro 
insulinotropic activities. Examples include cardiotoxin-I from Naja 
kaouthia venom (Nguyen et al., 2014), a [Lys49]phospholipase A2 iso-
form from Bothrops jararacussu venom (Fagundes et al., 2011) and 
phospholipases A2 and disintegrins from the venoms of Crotalus ada-
manteus, Crotalus vegrandis and Bitis nasicornis (Moore et al., 2015). 
The black-necked spitting cobra Naja nigricollis (Hallowell, 1857) 
(Elapidae) is widely distributed and common in sub-Saharan Africa. The 
species usually inhabits savanna and semi-desert regions at altitudes up 
to 1800 m but has demonstrated an ability to adapt to life in farmland 
regions. Although the mortality rate in untreated cases of snakebite is 
relatively low (5–10%), the species can project venom, which is a 
powerful irritant to the eyes, with remarkable accuracy. The resulting 
ophthalmia can result in permanent blindness (Goldman and Seefeld, 
2010). 
The aim of the present study was to analyse venom samples from 
N. nigricollis collected in Nigeria for the presence of components with 
potential for development into anticancer agents by determining their 
cytotoxic activities against A549 human non-small cell lung adenocar-
cinoma cells, MDA-MB-231 human breast adenocarcinoma cells, and 
HT-29 human colorectal adenocarcinoma cells. Their activities against 
tumor cells was compared with cytotoxic activity against HUVEC human 
umbilical vein endothelial cells. In addition, the presence of components 
in the venom with potential for development in agents for use in T2DM 
therapy was investigated by determining their abilities to stimulate the 
release of insulin in vitro using BRIN-BD11 rat clonal β-cells. 
2. Materials and methods 
2.1. Cytotoxicity assays 
The presence of cytotoxic peptides in chromatographic effluent was 
monitored by incubation of lyophilized aliquots (20 μL) with BRIN-BD11 
clonal β-cells (McClenaghan et al., 1996) for 20 min at 37 �C in 
Krebs-Ringer bicarbonate (KRB) buffer supplemented with 5.6 mM 
glucose. The rate of lactate dehydrogenase (LDH) release was deter-
mined using a CytoTox 96 non-radioactive cytotoxicity assay kit 
(Promega, Southampton, UK) according to the manufacturer’s 
instructions as previously described (Owolabi et al., 2016). 
A549 human non-small cell lung adenocarcinoma cells were main-
tained at 37 �C in RPMI 1640 medium containing 2 mM L-glutamine and 
supplemented with 10% fetal calf serum (FCS, Biowest, Nouaille, 
France), and antibiotics (penicillin 50 U/mL; streptomycin 50 μg/mL) 
(Attoub et al., 2013). MDA-MB-231 human breast adenocarcinoma cells 
and HT-29 human colorectal adenocarcinoma cells were maintained in 
Dulbecco’s Modified Eagle’s Medium supplemented with antibiotics 
(penicillin 50U/mL; streptomycin 50 μg/mL) and 10% FCS (Attoub 
et al., 2013). EndoGRO human umbilical vein endothelial cells 
(HUVECs) were maintained in EndoGRO MV-VEGF Complete Media Kit 
(Millipore, Temecula, CA, USA) (Conlon et al., 2013). In all experiments, 
cell viability was higher than 99% using trypan blue dye exclusion. Cells 
were seeded in 96-well plates at a density of 5 � 103 cells/well. After 24 
h incubation, cells were treated for 24 h with increasing concentrations 
of the purified toxins (0.3–30 μM) in triplicate. The effect of the peptides 
on cell viability was determined by measurement of ATP concentrations 
using a CellTiter-Glo Luminescent Cell Viability assay (Promega Cor-
poration, Madison, WI, USA). Luminescent signals were measured using 
a GLOMAX Luminometer system. The LC50 value, calculated by 
non-linear regression analysis using commercially available software 
(GraphPad Prism version 5), was taken as the mean concentration of 
peptide producing 50% cell death in three independent experiments. 
In order to determine hemolytic activity, peptides in the concentra-
tion range 11–90 μM were incubated in triplicate with washed eryth-
rocytes (2 � 107 cells) from NIH Swiss mice in KRB buffer pH 7.4 (100 
μL) for 1 h at 37 �C. After centrifugation (12,000�g for 15 s), the 
absorbance at 450 nm of the supernatant was measured. A parallel in-
cubation in the presence of 1% v/v Triton-X100 was carried out to 
determine the absorbance associated with 100% hemolysis. The LC50 
value was taken as the mean concentration of peptide producing 50% 
hemolysis in two independent experiments. 
2.2. In vitro insulin release studies using BRIN-BD11 cells 
The procedure for studying the effects of peptides on the release of 
insulin from BRIN-BD11 rat clonal β-cells has been described in detail 
previously (Owolabi et al., 2016). Incubations with fractions of chro-
matographic effluent and with N. nigricollis phospholipase A2 (PLA2) 
isoforms (1 μM; n ¼ 4) were carried out for 20 min at 37 �C using KRB 
buffer supplemented with 5.6 mM glucose. After incubation, aliquots of 
cell supernatant were removed for insulin radioimmunoassay (Flatt and 
Bailey, 1981). Incubations (n ¼ 4) of BRIN-BD11 cells with the estab-
lished insulin secretagogue, alanine (10 mM) were carried out in 
parallel. 
2.3. Purification of the cytotoxic peptides 
A pooled sample of venom was prepared from adult specimens of 
N. nigricollis from Nigeria that were housed at the Liverpool School of 
Tropical Medicine. In the first chromatography, the lyophilized venom 
sample (550 μg) was redissolved in 0.1% (v/v) trifluoroacetic acid 
(TFA)/water (2 mL) and injected onto a (1.0 cm � 25 cm) Vydac 
218TP510 (C-18) reversed-phase HPLC column (Grace, Deerfield, IL, 
USA) equilibrated with 0.1% (v/v) TFA/water at a flow rate of 2.0 mL/ 
min. The concentration of acetonitrile in the eluting solvent was raised 
to 21% (v/v) over 10 min and to 63% (v/v) over 60 min using linear 
gradients. Absorbance was monitored at 214 nm and fractions (1 min) 
were collected. Freeze-dried aliquots (20 μL) of the fractions were 
reconstituted in KRB buffer (100 μL) and their abilities to produce 
cytolysis of BRIN-BD11 cells were determined as described in the cyto-
toxicity assays section. Fractions containing peptides with cytotoxic 
activity were successively chromatographed on a (1 cm � 25 cm) Vydac 
214TP510 (C-4) column and a (1 cm � 25 cm) Vydac 208TP510 (C-8) 
column at a flow rate of 2.0 mL/min. The concentration of acetonitrile in 
the eluting solvent was raised from 21% to 56% over 50 min using a 
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linear gradient. The purified peptides were analysed by MALDI-ToF 
mass spectrometry using a Bruker UltraFlextreme instrument as previ-
ously described (Conlon et al., 2018b). 
In the second preparative chromatography, the venom sample (20 
mg) was redissolved in 0.1% (v/v) TFA/water (4 mL) and the total 
amount injected onto a (2.2 cm � 25 cm) Vydac 218TP1022 (C-18) 
reversed-phase HPLC column equilibrated with 0.1% (v/v) TFA/water 
at a flow rate of 6.0 mL/min. The concentration of acetonitrile in the 
eluting solvent was raised to 21% (v/v) over 10 min and to 63% (v/v) 
over 60 min using linear gradients. The major peaks in the chromato-
gram were collected by hand and peptides/proteins were purified to 
near homogeneity (>98% purity) on semi-preparative Vydac C-4 and C- 
8 columns as described above. 
2.4. Proteomic analysis of the purified toxins 
The molecular masses of the purified components were determined 
by nano-Acquity Ultra Performance LC (Waters Corporation, Milford, 
MA, USA) using a BEH130 C-18 (100 μm � 100 mm, 1.7 μm particle 
size) column in-line with a Waters SYNAPT G2 High Definition Mass 
Spectrometry System. The flow rate was set to 0.6 μL/min and the col-
umn was developed with a linear gradient of 0.1% formic acid in water 
(solution A) and 0.1% formic acid in acetonitrile (solution B), isocrati-
cally 1% B for 1 min, followed by 1–12% B for 1min, 12–40% B for 
15min, 40–85% B for 2 min. Isotope-averaged molecular masses were 
calculated by manual deconvolution of the isotope-resolved multiply- 
charged MS1 mass spectra. 
The purified cytotoxic peptides were initially analysed by SDS-PAGE 
on 15% polyacrylamide gels under reducing and non-reducing condi-
tions and the protein bands were excised from Coomassie Brilliant Blue- 
stained gels and subjected to automated reduction, alkylation, and in-gel 
digestion with sequencing grade porcine pancreatic trypsin using a 
Progest™ digestor (Genomic Solutions, Ann Arbor, MI, USA). Tryptic 
digests were dried in a SpeedVac vacuum centrifuge, redissolved in 14 
μL of 5% acetonitrile containing 0.1% formic acid and submitted to LC- 
MS/MS. Tryptic peptides were separated by nano-Acquity Ultra Per-
formance LC as described above. Doubly and triply charged ions were 
selected for collision-induce dissociation (CID)-MS/MS. Fragmentation 
spectra were interpreted (a) manually (de novo sequencing), (b) using 
the on-line form of the MASCOT Server (version 2.6) at http://www. 
matrixscience.com against the last update (Release 234 of October 
15th, 2019) of the NCBI non-redundant database, and (c) processed in 
the Waters Corporation’s ProteinLynx Global SERVER 2013 version 
2.5.2. (with Expression version 2.0). The following search parameters 
were used: Taxonomy: bony vertebrates; Enzyme: trypsin (two missed 
cleavage allowed); MS/MS mass tolerance was set to � 0.6 Da; carba-
midomethyl cysteine and oxidation of methionine were selected as fixed 
and variable modifications, respectively. All matched MS/MS data were 
manually checked. Peptide sequences assigned by de novo MS/MS were 
matched to homologous proteins available in the NCBI non-redundant 
protein sequences database using the online BLASTP program at 
https://blast.ncbi.nlm.nih.gov/Blast.cgi. 
3. Results 
3.1. Purification of the cytotoxic and insulin-releasing peptides 
The elution profile on a semi-preparative Vydac C-18 column of a 
small amount (550 μg) of the venom from N. nigricollis is shown in 
Fig. 1A. Under the conditions of assay, the peaks designated 1, 4, and 7 
contained components that displayed strong cytotoxic activity (>98% 
cell death) against BRIN-BD11 cells during a 20 min incubation and 
against A549 cells during a 24 h incubation. The peaks designated 1–5 
and 7 contained components that stimulated the rate of insulin release 
from BRIN-BD11 cells. The peptide present in peak 6 displayed weak 
cytotoxic activity against BRIN-BD11 and A549 cells and did not 
stimulate insulin release from BRIN-BD11 cells. 
The fractions were analysed by MALDI-ToF mass spectrometry and 
the molecular masses of the proteins present in peaks 8 and 9 were 
>20,000 Da and these components did not display cytotoxicity against 
A549 cells and BRIN-BD11 cells and did not stimulate insulin release. A 
comparison of the HPLC chromatogram shown in Fig. 1A with those 
from a range of species belonging to the genus Naja (Petras et al., 2011) 
suggests that these proteins belong to the snake venom metal-
loproteinase (SVMP) family. Purification to near homogeneity, as 
assessed by a symmetrical peak shape and mass spectrometry, of the 
components in peaks 1–4, 6 and 7 was accomplished by chromatography 
on a semi-preparative Vydac C-4 and C-8 columns. The material in peak 
5 was too heterogenous to permit isolation of individual components. 
In order to obtain sufficient pure material for assessment of biolog-
ical activity, a larger quantity (20.0 mg) of venom was chromatographed 
on a preparative Vydac C-18 column (Fig. 1B). The peak designated 2 þ
3 contained both phospholipase A2 -1N and phospholipase A2-2N and 
peak designate 4 þ 5 contained cytotoxin-2N and several 
Fig. 1. Reversed-phase HPLC on (A) a semi-preparative Vydac C-18 column of 
venom (550 μg dry weight) and (B) a preparative Vydac C-18 column of venom 
(20 mg dry weight) from N. nigricollis. In panel A, the peaks designated 1 and 
4–7 contained components that displayed strong cytotoxic activity against 
BRIN-BD11 clonal β-cells. The peaks designated 1–5 and 7 contained compo-
nents that stimulated the rate of insulin release from BRIN-BD11 cells. In panel 
B, material in peaks 1, 2 þ 3, 4 þ 5, 6 and 7 were purified to near homogeneity 
by further chromatography on Vydac C-4 and C-8 columns. The dashed line 
shows the concentration of acetonitrile in the eluting solvent. 
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uncharacterized components. The components were purified to near 
homogeneity on Vydac C-4 and C-8 columns as previously described. 
The methodology is illustrated by the separation of the two isoforms of 
phospholipase A2 on a semipreparative Vydac C-4 column (Fig. 2A) and 
purification to near homogeneity, as assessed by symmetrical peak 
shape and mass spectrometry, of phospholipase A2-1N on a semi-
preparative Vydac C-8 column (Fig. 2B). The yields of the purified 
components, determined by dry weight using an ultramicrobalance, 
were peak 1 peptide (subsequently shown to be cytotoxin-1N) 1020 μg, 
peak 2 protein (phospholipase A2-1N) 480 μg, peak 3 protein (phos-
pholipase A2-2N) 680 μg, peak 4 peptide (cytotoxin-2N) 525 μg, peak 6 
peptide (cytotoxin-3N) 270 μg, and peak 7 peptide (cytotoxin-4N) 1635 
μg. The molecular masses of the purified peptides determined by elec-
trospray ionization (ESI) mass spectrometry are shown in Supplemen-
tary Figs. 1A–F. 
3.2. Identification of the cytotoxic peptides 
The identities of the peptides were determined by CID-MS/MS mass 
spectrometric analysis of fragments generated by in-gel tryptic diges-
tion. The primary structures of these fragments are shown aligned to the 
best database hit in Fig. 3. Peak 1 peptide (Fig. 1A), designated 
cytotoxin-1N (average native molecular mass [M]av ¼ 6743.6 Da) was 
identified as a three-finger toxin (3FTx) by sequence similarity with 
cytotoxin-4 (also known as cardiotoxin V(II)4) from the Mozambique 
spitting cobra Naja mossambica (UniProtKB: P01452). Peak 4 peptide 
(Fig. 1A), designated cytotoxin-2N, ([M]av ¼ 6887.3 Da) was identified 
as a 3FTx by sequence similarity with the anticoagulant peptide nani-
proin (PODSN1) from N. nigricollis. Peak 7 peptide (Fig. 1A) 
([M]av¼6819.1 Da) was identified as a 3FTx toxin by sequence similarity 
with cytotoxin-1 (also known as cardiotoxin IIB) from N. mossambica 
(P01467). The average molecular mass of cytotoxin-3N was 6686.6 Da. 
A peptide with this molecular mass and similar retention time on HPLC 
was previously detected in N. nigricollis venom collected in Nigeria and 
was identified as a 3FTx family member on the basis of N-terminal 
sequence similarity (Petras et al., 2011). ESI-MS/MS sequencing of two 
tryptic peptides confirmed the assignment of cytotoxin-3N to the 
ortholog 3FTx of N. mossambica cytotoxin-5 (P25517) (Fig. 3). 
3.3. Identification of the insulin-releasing peptides 
The protein in peak 2 (Fig. 1A), designated PLA2-1N ([M]av ¼
13,221.6 Da) was identified as belonging to the [Asp]49phospholipase 
A2 family by sequence similarity with phospholipase A2 isozyme III from 
N. nigricollis (P00605). The protein in peak 3 (Fig. 1A), designated PLA2- 
2N ([M]av ¼ 13,289.0 Da) was identified as belonging to the [Asp]49 
PLA2 family by sequence similarity with basic PLA2 CM-II from 
N. mossambica (P00603) (Fig. 3). 
3.4. Cytotoxic activities of the peptides 
The effects of increasing concentrations of the purified three-finger 
toxins on the viability of A549 human non-small cell lung adenocarci-
noma cells, MDA-MB-231 breast adenocarcinoma cells, HT-29 colorectal 
adenocarcinoma cells, and HUVEC human umbilical vein endothelial 
cells are shown in Fig. 4. The LC50 values are shown in Table 1. 
Consistent with previous data relating to 3FTxs from the Eastern green 
mamba Dendroaspis angusticeps (Elapidae) (Conlon et al., 2014), A549 
cells were the most sensitive to the cytotoxic action of the peptides and 
HT-29 cells were the most resistant. Cytotoxin-2N was the only peptide 
tested with appreciable hemolytic activity against mouse erythrocytes 
(LC50 ¼ 45 � 3 μM) (Table 1). 
3.5. Insulin-releasing activity of the peptides 
Under the conditions of assay, chromatographic fractions containing 
cytotoxins-1, -2, and -4 stimulated insulin release from BRIN-BD11 
clonal β-cells. However, at the same concentration, the toxins also 
markedly stimulated release of the cytosolic enzyme LDH indicating that 
the integrity of the plasma membrane had been compromised (data not 
shown). In contrast, fractions containing PLA2-1N and PLA2-2N stimu-
lated insulin release from BRIN-BD11 cells at concentrations that did not 
result in increased release of LDH. There was insufficient pure material 
to investigate concentration-response effects in detail but incubation 
with PLA2-1N(1 μM) with BRIN-BD11 cells produced an increase in the 
rate of insulin-release from 1.1 � 0.1 ng/106 cells/20 min in the pres-
ence of 5.6 mM glucose alone to 6.9 � 0.4 ng/106 cells/20 min. The 
corresponding rate of insulin-release produced by incubation with PLA2- 
2N (1 μM) was 6.5 � 0.4 ng/106 cells/20 min. At this concentration, 
there was no significant increase in the rate of LDH release. Parallel 
incubations with 10 mM alanine produced an increase in rate of insulin 
release to 6.6 � 0.5 ng/106 cells/20 min. 
4. Discussion 
The venom of the spitting cobra N. nigricollis is a repository of several 
Fig. 2. Partial separation of the phospholipase A2-1 N (peak 1) and phospholipase A2-2 N (peak 2) (derived from peak 2 þ 3 in Fig. 1B) on a semipreparative Vydac 
C-4 column (Panel A), and purification to near homogeneity of phospholipase A2-1 N (peak 1) on a semipreparative Vydac C-8 column (Panel B). The arrowheads 
show where peak collection began and ended. The dashed line shows the concentration of acetonitrile in the eluting solvent. 
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structurally well characterized peptides and proteins whose diverse 
biological activities have been investigated in detail. These include the 
membrane-damaging cardiotoxin, toxin γ (Kao et al., 2009), toxin α, a 
neurotoxin that specifically blocks the activity of the nicotinic acetyl-
choline receptor (Zinn-Justin et al., 1992), nawaprin, a peptide that is 
structurally, but not functionally, related to the human leukocyte 
elastase-specific inhibitor, elafin (Torres et al., 2003), the basic and 
strongly anticoagulant phospholipase A2 CM-IV, and the weakly anti-
coagulant phospholipases A2 CM-1 and CM-II (Kini, 2005). The aim of 
the present study was to examine N. nigricollis venom for the presence of 
components with therapeutic potential for development of anti-cancer 
and anti-diabetic agents. 
The study has led to the purification of four peptides in whose partial 
structures, obtained by MS/MS analysis of tryptic fragments, identify 
them as members of the widely distributed 3FTx superfamily (Kini and 
Doley, 2010; Utkin, 2013). Peptides in this family are characterized by 
three β-stranded loops emerging from a globular core that are stabilized 
by four or five disulfide bridges. 3FTx peptides are not confined to the 
venoms of elapids (mambas, cobras, and kraits) but have also been 
identified the venoms of colubrids, hydrophiids and vipers and more 
than 500 members have been described (Utkin, 2013). Despite the 
overall similarity in conformation, the biological properties of 3FTx 
peptides vary greatly. They may function as postsynaptic neurotoxins 
targeting the nicotinic and muscarinic acetylcholine receptors, 
β-blockers targeting β1-and β2-adrenergic receptors, antagonists of α1A 
and α2A adrenergic receptors, blockers of L-type calcium channels, as 
well as cardiotoxins targeting phospholipid membranes and anticoagu-
lants targeting various coagulation complexes [reviewed in (Girish et al., 
2012)]. 
The 3FTx peptides cytotoxin-1N, -2N, and –4N isolated from 
N. nigricollis venom display potent and concentration-dependent cyto-
toxic activity against three diverse human tumor-derived cell lines but 
their potential for development into therapeutically valuable anti- 
cancer agents is low because of their strong cytotoxicity against a cell 
line derived from non-neoplastic tissue. In addition, cytotoxin-2N was 
appreciably hemolytic. These peptides also stimulated insulin release 
from a rat clonal β-cell line but only a concentration that also stimulated 
release of the cytosolic enzyme LDH. It is concluded, therefore, the 
Fig. 3. Identification of the cytotoxins from N. nigricollis venom by comparison of the primary structures of their tryptic peptides (shown in red) with the structures of 
corresponding regions of known toxins. The sequences of cytotoxins-1, -4, and -5 and PLA2-2 N are from N. mossambica and the sequences of naniproin and PLA2-1 N 
are from N. nigricollis. 
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insulinotropic activity of these peptides is, at least in part, a non-specific 
consequence of cell necrosis. 
Like 3FTx peptides, members of the PLA2 (EC 3.1.1.4) enzyme family 
are widely distributed in venoms from Elapidae, Hydrophidae, and 
Viperidae species and exhibit a diverse range of biological activities. 
With very few exceptions, PLA2 proteins in the venom of Naja spp. 
contain an Asp residue at position 49 and, as well as catalyzing the 
hydrolysis of the sn-2 ester bond in a variety of different phospholipids, 
Fig. 4. Effects of cytotoxin-1N, cytotoxin-2N, cytotoxin-3N and cytotoxin-4N from N. nigricollis venom on the viability of A549 non-small cell lung adenocarcinoma 
cells; MDA-MB-231 breast adenocarcinoma cells; HT-29 colorectal adenocarcinoma cells; and HUVEC umbilical vein endothelial cells All experiments were repeated 
at least three times. Columns: mean; bars: SEM. 
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have been shown to exhibit antimicrobial, neurotoxic, myotoxic, anti-
coagulant, prostaglandin-mediated hypotensive, inflammatory, and 
antiangiogenic properties [reviewed in (Xiao et al., 2017; Trento et al., 
2019)]. The venoms of species of the Viperidae family may also contain 
multiple molecular forms of [Lys49]PLA2 that are enzymatically inactive 
and [Ser49]PLA2 that are weakly esterolytic. These components 
frequently display high cytotoxic potency against a range of mammalian 
cell types, including tumor cells (Sobrinho et al., 2016) and make an 
important contribution to the local tissue necrosis and damage to the 
vasculature observed at the site of the snakebite (Conlon et al., 2013; 
Guti�errez et al., 2018). 
Both isoforms of [Asp49]PLA2 isolated from the venom of N. nigricollis 
effectively stimulate insulin release from BRIN-BD11 rat clonal β-cells 
(an approximately 6-fold increase in rate at a concentration of 1 μM). At 
this concentration, the proteins did not stimulate LDH release indicating 
that they are not cytotoxic to the cells. The early stages of T2DM may be 
associated with hypersecretion of insulin to overcome insulin resistance 
but, as the disease progresses, impaired β-cell secretion becomes 
apparent. Several cytotoxic peptides present in norepinephrine- 
stimulated frog skin secretions that were first identified on the basis of 
their antimicrobial actions have been shown to stimulate insulin release 
in vitro from BRIN-BD11 cells and isolated mouse islets and in animal 
models of T2DM [reviewed in (Conlon et al., 2018a)]. In addition, 
certain frog skin peptides belonging to the esculentin-1a (Musale et al., 
2018a) and temporin (Musale et al., 2018b) families protect BRIN-BD11 
cells against cytokine-induced apoptosis and augment proliferation of 
the cells. The strong insulinotropic activity of PLA2-1 N and PLA2-2 N 
suggests that they may represent templates for development in agents 
with a role in the treatment of patients with T2DM. With the availability 
of more purified material, future studies will investigate whether the 
proteins may also function as β-cell proliferative and protective agents in 
vitro and as antihyperglycaemic agents in a rodent model of T2DM such 
as mice with diet-induced obesity, glucose-intolerance, and insulin 
resistance (O’Harte et al., 2016). 
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Formal analysis. J�erôme Leprince: Investigation, Data curation, Formal 
analysis. Nicholas R. Casewell: Conceptualization, Resources. Libia 
Sanz: Investigation, Data curation, Formal analysis. Juan J. Calvete: 
Investigation, Data curation, Formal analysis, Writing - original draft, 
Writing - review & editing. 
Acknowledgements 
This work was partly supported by the Ministerio de Ciencia, 
Innovaci�on y Universidades, Madrid, Spain (grant number BFU 2017- 
89103-P) to JJC. The authors thank Kholoud Arafat, U.A.E. University 
and Gervonne Barran, University of the West Indies for technical 
assistance. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.toxcx.2020.100030. 
References 
Allane, D., Oussedik-Oumehdi, H., Harrat, Z., Seve, M., Laraba-Djebari, F., 2018. 
Isolation and characterization of an anti-leishmanial disintegrin from Cerastes 
cerastes venom. J. Biochem. Mol. Toxicol. 32. https://doi: 10.1002/jbt.22018. 
Almeida, J.R., Resende, L.M., Watanabe, R.K., Carregari, V.C., Huancahuire-Vega, S., da 
S Caldeira, C.A., Coutinho-Neto, A., Soares, A.M., Vale, N., de C Gomes, P.A., 
Marangoni, S., de A Calderon, L., Da Silva, S.L., 2017. Snake venom peptides and low 
mass proteins: molecular tools and therapeutic agents. Curr. Med. Chem. 24, 
3254–3282. https://doi: 10.2174/0929867323666161028155611. 
Attoub, S., Arafat, H., Mechkarska, M., Conlon, J.M., 2013. Anti-tumor activities of the 
host-defense peptide hymenochirin-1B. Regul. Pept. 187, 51–56. https://doi: 10.10 
16/j.regpep.2013.10.006. 
Bailey, C.J., 2018. Glucose-lowering therapies in type 2 diabetes: opportunities and 
challenges for peptides. Peptides 100, 9–17. https://doi: 10.1016/j.peptides.2017.11 
.012. 
Brzezicki, M.A., Zakowicz, P.T., 2018. Mambalgins, the venom-origin peptides as a 
potentially novel group of analgesics: mini review. CNS Neurol. Disord. - Drug 
Targets 17, 87–97. https://doi: 10.2174/1871527317666171221110419. 
Calvete, J.J., 2018. Snake venomics - from low-resolution toxin-pattern recognition to 
toxin-resolved venom proteomes with absolute quantification. Expert Rev. 
Proteomics 15, 555–568. https://doi: 10.1080/14789450.2018.1500904. 
Cavalcante, C.S., Falc~ao, C.B., Fontenelle, R.O., Andreu, D., R�adis-Baptista, G., 2017. 
Anti-fungal activity of Ctn[15-34], the C-terminal peptide fragment of crotalicidin, a 
rattlesnake venom gland cathelicidin. J. Antibiot. (Tokyo) 70, 231–237. https://doi: 
10.1038/ja.2016.135. 
Charvat, R.A., Strobel, R.M., Pasternak, M.A., Klass, S.M., Rheubert, J.L., 2018. Analysis 
of snake venom composition and antimicrobial activity. Toxicon 50, 151–167. 
https://doi: 10.1016/j.toxicon.2018.05.016. 
Chen, M., Aoki-Utsubo, C., Kameoka, M., Deng, L., Terada, Y., Kamitani, W., Sato, K., 
Koyanagi, Y., Hijikata, M., Shindo, K., Noda, T., Kohara, M., Hotta, H., 2017. Broad- 
spectrum antiviral agents: secreted phospholipase A2 targets viral envelope lipid 
bilayers derived from the endoplasmic reticulum membrane. Sci. Rep. 7, 15931. 
https://doi: 10.1038/s41598-017-16130-w. 
Conlon, J.M., Attoub, S., Arafat, H., Mechkarska, M., Casewell, N.R., Harrison, R.A., 
Calvete, J.J., 2013. Cytotoxic activities of [Ser⁴⁹]phospholipase A₂ from the venom of 
the saw-scaled vipers Echis ocellatus, Echis pyramidum leakeyi, Echis carinatus 
sochureki, and Echis coloratus. Toxicon 71, 96–104. https://doi: 10.1016/j.toxicon.20 
13.05.017. 
Conlon, J.M., Prajeep, M., Mechkarska, M., Arafat, K., Attoub, S., Adem, A., Pla, D., 
Calvete, J.J., 2014. Peptides with in vitro anti-tumor activity from the venom of the 
Eastern green mamba, Dendroaspis angusticeps (Elapidae). J. Venom Res. 5, 16–21. 
PMID: 25035794.  
Conlon, J.M., Mechkarska, M., Abdel-Wahab, Y.H., Flatt, P.R., 2018a. Peptides from frog 
skin with potential for development into agents for Type 2 diabetes therapy. Peptides 
100, 275–281. https://doi: 10.1016/j.peptides.2017.09.001. 
Conlon, J.M., Moffett, R.C., Leprince, J., Flatt, P.R., 2018b. Identification of components 
in frog skin secretions with therapeutic potential as antidiabetic agents. Methods 
Mol. Biol. 1719, 319–333. https://doi: 10.1007/978-1-4939-7537-2_21. 
Estev~ao-Costa, M.I., Sanz-Soler, R., Johanningmeier, B., Eble, J.A., 2018. Snake venom 
components in medicine: from the symbolic rod of Asclepius to tangible medical 
research and application. Int. J. Biochem. Cell Biol. 104, 94–113. https://doi: 10.10 
16/j.biocel.2018.09.011. 
Fagundes, F.H., Aparício, R., dos Santos, M.L., Diz Filho, E.B., Oliveira, S.C., Toyama, D. 
O., Toyama, M.H., 2011. A catalytically inactive Lys49 PLA2 isoform from Bothrops 
jararacussu venom that stimulates insulin secretion in pancreatic beta cells. Protein 
Pept. Lett. 18, 1133–1139. https://doi: 10.2174/092986611797200940. 
Table 1 
Cytotoxicities of cytotoxins from N. nigricollis venom against human non-small 
cell lung adenocarcinoma A549 cells, breast adenocarcinoma MDA-MB-231 
cells, colorectal adenocarcinoma HT-29 cells, human umbilical vein endothelial 
HUVEC cells and mouse red blood cells (RBC).  
Peptide A549 MDA-MB-231 HT-29 HUVEC RBC 
Cytotoxin-1N 0.8 � 0.2 7 � 1 9 � 1 7 � 1 >90 (20) 
Cytotoxin-2N 1.4 � 0.2 6 � 1 8 � 1 7 � 1 45 � 3 
Cytotoxin-3N 7 � 1 >30 >30 22 � 2 ND 
Cytotoxin-4N 0.9 � 0.2 8 � 1 25 � 3 2 � 0.2 >90 (12) 
Data show LC50 values (μM) � S.E.M. ND: not determined. The values in pa-
rentheses show the % hemolysis at 90 μM. 
J.M. Conlon et al.                                                                                                                                                                                                                               
Toxicon: X 6 (2020) 100030
8
Flatt, P.R., Bailey, C.J., 1981. Abnormal plasma glucose and insulin responses in 
heterozygous lean (ob/þ) mice. Diabete 20, 573–577. https://doi: 10.1007/b 
f00252768. 
Girish, V.M., Kumar, S., Joseph, L., Jobichen, C., Kini, R.M., Sivaraman, J., 2012. 
Identification and structural characterization of a new three-finger toxin 
hemachatoxin from Hemachatus haemachatus venom. PloS One 7, e48112. 
https://doi: 10.1371/journal.pone.0048112. 
Goldman, D.R., Seefeld, A.W., 2010. Ocular toxicity associated with indirect exposure to 
African spitting cobra venom. Wilderness Environ. Med. 21, 134–136. https://doi: 
10.1016/j.wem.2009.12.007. 
Guti�errez, J.M., Escalante, T., Hern�andez, R., Gastaldello, S., Saravia-Otten, P., 
Rucavado, A., 2018. Why is skeletal muscle regeneration impaired after myonecrosis 
induced by viperid snake venoms? Toxins 10 pii: E182. https://doi: 10.3390/toxin 
s10050182. 
Kao, P.H., Wu, M.J., Chang, L.S., 2009. Membrane-bound conformation of Naja nigricollis 
toxin gamma affects its membrane-damaging activity. Toxicon 53, 342–348. 
https://doi: 10.1016/j.toxicon.2008.12.003. 
Khan, S., Gul, A., Noreen, R., Ahmed, S., Ashraf, M., Awan, M.S.B., Niazi, Z.R., Khan, N., 
2018. Potential applications of venom peptides as anti-thrombotic agents for 
management of arterial and deep-vein thrombosis. Protein Pept. Lett. 25, 677–687. 
https://doi: 10.2174/0929866524666180614100101. 
Kini, R.M., 2005. Structure-function relationships and mechanism of anticoagulant 
phospholipase A2 enzymes from snake venoms. Toxicon 45, 1147–1161. https://doi: 
10.1016/j.toxicon.2005.02.018. 
Kini, R.M., Doley, R., 2010. Structure, function and evolution of three-finger toxins: mini 
proteins with multiple targets. Toxicon 56, 855–867. https://doi: 10.1016/j.toxicon. 
2010.07.010. 
Lazarovici, P., 2020. Snake- and spider-venom-derived toxins as lead compounds for 
drug development. Methods Mol. Biol. 2068, 3–26. https://doi: 10.1007/978-1-4939 
-9845-6_1. 
Lord, C.J., Ashworth, A., 2013. Mechanisms of resistance to therapies targeting BRCA- 
mutant cancers. Nat. Med. 9, 1381–13888. https://doi: 10.1038/nm.3369. 
McClenaghan, N.H., Barnett, C.R., Ah-Sing, E., Abdel-Wahab, Y.H., O’Harte, F.P., 
Yoon, T.W., Swanston-Flatt, S.K., Flatt, P.R., 1996. Characterization of a novel 
glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by 
electrofusion. Diabetes 45, 1132–1140. https://doi.org/10.2337/diab.45.8.1132. 
Moore, S.W., Bhat, V.K., Flatt, P.R., Gault, V.A., McClean, S., 2015. Isolation and 
characterisation of insulin-releasing compounds from Crotalus adamanteus, Crotalus 
vegrandis and Bitis nasicornis venom. Toxicon 101, 48–54. https://doi: 10.1016/j. 
toxicon.2015.05.002. 
Musale, V., Abdel-Wahab, Y.H.A., Flatt, P.R., Conlon, J.M., Mangoni, M.L., 2018a. 
Insulinotropic, glucose-lowering, and beta-cell anti-apoptotic actions of peptides 
related to esculentin-1a(1-21).NH2. Amino Acids 50, 723–734. https://doi: 10.100 
7/s00726-018-2551-5. 
Musale, V., Casciaro, B., Mangoni, M.L., Abdel-Wahab, Y.H.A., Flatt, P.R., Conlon, J.M., 
2018b. Assessment of the potential of temporin peptides from the frog Rana 
temporaria (Ranidae) as anti-diabetic agents. J. Pept. Sci. 24, e3065. https://doi: 
10.1002/psc.3065. 
Nguyen, T.T., Folch, B., L�etourneau, M., Truong, N.H., Doucet, N., Fournier, A., 
Chatenet, D., 2014. Design of a truncated cardiotoxin-I analogue with potent 
insulinotropic activity. J. Med. Chem. 57, 2623–2633. https://doi: 10.1021/ 
jm401904q. 
O’Harte, F.P.M., Ng, M.T., Lynch, A.M., Conlon, J.M., Flatt, P.R., 2016. Dogfish glucagon 
analogues counter hyperglycaemia and enhance both insulin secretion and action in 
diet-induced obese diabetic mice. Diabetes Obes. Metabol. 18, 1013–1024. https:// 
doi: 10.1111/dom.12713. 
Owolabi, B.O., Ojo, O.O., Srinivasan, D.K., Conlon, J.M., Flatt, P.R., Abdel-Wahab, Y.H., 
2016. In vitro and in vivo insulinotropic properties of the multifunctional frog skin 
peptide hymenochirin-1B: a structure-activity study. Amino Acids 48, 535–547. 
https://doi: 10.1007/s00726-015-2107-x. 
Petras, D., Sanz, L., Segura, A., Herrera, M., Villalta, M., Solano, D., Vargas, M., Le�on, G., 
Warrell, D.A., Theakston, R.D., Harrison, R.A., Durfa, N., Nasidi, A., Guti�errez, J.M., 
Calvete, J.J., 2011. Snake venomics of African spitting cobras: toxin composition and 
assessment of congeneric cross-reactivity of the pan-African EchiTAb-Plus-ICP 
antivenom by antivenomics and neutralization approaches. J. Proteome Res. 10, 
1266–1280. https://doi: 10.1021/pr101040f. 
Sartim, M.A., Menaldo, D.L., Sampaio, S.V., 2018. Immunotherapeutic potential of 
Crotoxin: anti-inflammatory and immunosuppressive properties. J. Venom. Anim. 
Toxins Incl. Trop. Dis. 17 (24), 39. https://doi: 10.1186/s40409-018-0178-3. 
Sobrinho, J.C., Sim~oes-Silva, R., Holanda, R.J., Alfonso, J., Gomez, A.F., Zanchi, F.B., 
Moreira-Dill, L.S., Grabner, A.N., Zuliani, J.P., Calderon, L.A., Soares, A.M., 2016. 
Antitumoral potential of snake venom phospholipases A2 and synthetic peptides. 
Curr. Pharmaceut. Biotechnol. 7, 1201–1212. https://doi: 10.2174/13892010 
17666160808154250. 
Thakur, R., Chattopadhyay, P., Mukherjee, A.K., 2019. The wound healing potential of a 
pro-angiogenic peptide purified from Indian Russell’s viper (Daboia russelii) venom. 
Toxicon 165, 78–82. https://doi: 10.1016/j.toxicon.2019.04.009. 
Torres, A.M., Wong, H.Y., Desai, M., Moochhala, S., Kuchel, P.W., Kini, R.M., 2003. 
Identification of a novel family of proteins in snake venoms. Purification and 
structural characterization of nawaprin from Naja nigricollis snake venom. J. Biol. 
Chem. 278, 40097–400104. https://doi: 10.1074/jbc.M305322200. 
Trento, M.V.C., Sales, T.A., de Abreu, T.S., Braga, M.A., Cesar, P.H.S., Marques, T.R., 
Marcussi, S., 2019. Exploring the structural and functional aspects of the 
phospholipase A2 from Naja spp. Int. J. Biol. Macromol. 140, 49–58. https://doi: 10 
.1016/j.ijbiomac.2019.08.125. 
Utkin, Y.N., 2013. Three-finger toxins, a deadly weapon of elapid venom–milestones of 
discovery. Toxicon 62, 50–55. https://doi: 10.1016/j.toxicon.2012.09.007. 
Uzair, B., Atlas, N., Malik, S.B., Jamil, N., Ojuolape, S.T., Rehman, M.U., Khan, B.A., 
2018. Snake venom as an effective tool against colorectal cancer. Protein Pept. Lett. 
25, 626–632. https://doi: 10.2174/0929866525666180614112935. 
Vyas, V.K., Brahmbhatt, K., Bhatt, H., Parmar, U., 2013. Therapeutic potential of snake 
venom in cancer therapy: current perspectives. Asian Pac. J. Trop. Biomed. 3, 
156–162. https://doi: 10.1016/S2221-1691(13)60042-8. 
World Health Organisation Fact Sheet 2019 Snakebite Envenoming. Accessible at https 
://www.who.int/news-room/fact-sheets/detail/snakebite-envenoming. 
Xiao, H., Pan, H., Liao, K., Yang, M., Huang, C., 2017. Snake venom PLA2, a promising 
target for broad-spectrum antivenom drug development. BioMed Res. Int. 2017, 
6592820. https://doi: 10.1155/2017/6592820. 
Zainal Abidin, S.A., Lee, Y.Q., Othman, I., Naidu, R., 2019. Malaysian cobra venom: a 
potential source of anti-cancer therapeutic agents. Toxins 11 pii: E75. https://doi: 
10.3390/toxins11020075. 
Zinn-Justin, S., Roumestand, C., Gilquin, B., Bontems, F., M�enez, A., Toma, F., 1992. 
Three-dimensional solution structure of a curaremimetic toxin from Naja nigricollis 
venom: a proton NMR and molecular modelling study. Biochemistry 31, 
11335–11347. https://doi: 10.1021/bi00161a011. 
J.M. Conlon et al.                                                                                                                                                                                                                               
